MIRA PHARMACEUTICALS, INC. — Form 8-K
Filed September 1, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
MIRA Pharmaceuticals reported positive 7-day dose-range finding toxicology and toxicokinetic studies in rats and dogs for MIRA-55, an investigational oral non-opioid inflammatory pain candidate. Results characterized tolerability and systemic exposure across species and will inform dose selection for subsequent GLP-compliant studies. The company targets IND submission to FDA in Q1 2027, pending completion of remaining IND-enabling work.
Why this rating
Early-stage preclinical milestone advances lead program toward human studies in $16M market-cap company. Meaningful progress but significant regulatory/clinical risks remain before commercialization.
See more from September 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.